stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Gross margin
Haemonetics Corporation's gross margin over the twelve months to 30 September 2026 was 59.6%, up 0.6 percentage points from fiscal 2026 (59.0%). Over the past ten years it has ranged from 42.7% (fiscal 2017) to 59.0% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Medical Devices industry median of 57.8% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2026 | 59.0% | 4.00 |
| FY2025 | 55.0% | 2.21 |
| FY2024 | 52.8% | 0.20 |
| FY2023 | 52.6% | 1.73 |
| FY2022 | 50.9% | 5.20 |
| FY2021 | 45.7% | (3.32) |
| FY2020 | 49.0% | 5.87 |
| FY2019 | 43.2% | (2.42) |
| FY2018 | 45.6% | 2.86 |
| FY2017 | 42.7% | (1.95) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 61.8% | 1.99 |
| Jun 2026 | 59.8% | 2.53 |
| Mar 2026 | 57.2% | (2.48) |
| Dec 2025 | 59.7% | 0.21 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AXGN AxoGen, Inc. compare | 74.2% |
| IRTC iRhythm Holdings, Inc. compare | 72.3% |
| TXG 10x Genomics compare | 70.0% |
| LIVN LivaNova PLC compare | 67.8% |
| HAE Haemonetics Corporation | 59.6% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 51.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 51.3% |
| BRKR Bruker Corporation compare | 47.7% |
| ITGR Integer Holdings Corporation compare | 24.6% |
| Medical Devices industry median | 57.8% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement